Vaxess Technologies today announced positive interim results from a first-in-human trial of its influenza vaccine patch. Cambridge, Massachusetts-based Vaxess evaluated VX-103, a monovalent seasonal influenza vaccine patch. The trial included 45 healthy patients and evaluated the H1N1 influenza antigen from Vaxess’ partner, GC Biopharma. Delivery of the vaccine took place through the Vaxess Mimix patch. […]
Clinical Trials
Data backs gene therapy delivery system for treating type 2 diabetes from Fractyl Health
Fractyl Health today announced positive preclinical proof-of-concept data in an animal model for its gene therapy delivery platform for treating type 2 diabetes. The company, which develops the Revita diabetes reversal procedure, evaluated its Rejuva program. Rejuva, a novel device and AAV-mediated delivery platform, delivers gene therapy directly targeting the pancreas. This potentially embeds multiple […]
PharmaJet wins NIH grant to evaluate needle-free delivery of HPV immunization
PharmaJet announced today that it received a grant worth $800,000-plus from the NIH to evaluate its needle-free injection system. Golden, Colorado-based PharmaJet picked up a Phase II grant from the NIH (National Institutes of Health). It allows the company to evaluate the immunogenicity of the intradermal administration of human papillomavirus virus (HPV) vaccine. The study […]
How Sernova seeks to treat insulin-dependent diabetes with its Cell Pouch System
When Dr. Philip Toleikis joined Sernova in 2009, the company’s technology appeared as more of a concept than anything else. But, he saw the potential for something groundbreaking: A cure for type 1 diabetes (T1D). “I just thought it was an incredible idea,” said Toleikis, who serves as Sernova’s president and CEO. “We spent a […]
TriSalus releases positive data for its catheter-based drug delivery tech
TriSalus Life Sciences today announced positive clinical results for its Pressure-Enabled Regional Immuno-Oncology technology. The company, currently in the process of going public through a SPAC merger, filed a presentation for investors. It features information regarding its ongoing PERIO 01 and PERIO 02 clinical studies. The studies evaluate the TriNav pressure-enabled drug delivery technology for […]
Study supports Tandem t:slim X2 insulin pump for type 2 diabetes
Tandem Diabetes Care (Nasdaq:TNDM) announced that a study of adults with type 2 diabetes supported its automated insulin delivery system. The study evaluated adults with type 2 diabetes using the t:slim X2 insulin pump with Control-IQ technology. Patients achieved improvement in all clinical endpoints with the technology, which currently does not hold approval for type […]
Sernova to enroll second cohort in trial of Cell Pouch System for type 1 diabetes
Sernova announced today that it received approval for a protocol amendment in the trial of its Cell Pouch System for treating type 1 diabetes. London, Ontario-based Sernova designed its proprietary Cell Pouch System as an implantable and scalable medical device. It forms a natural environment in the body for the long-term survival and function of […]
BioCorRx completes enrollment in trial of naltrexone implant for treating opioid use disorder
BioCorRx (OTC:BICX) announced today that it enrolled the last subject in the Phase I clinical trial of its BICX104 implant. Anaheim, California-based BioCorRx designed BICX104 for the treatment of opioud use disorder (OUD). Its BioCorRx Pharmaceuticals company developed the implantable, biodegradable naltrexone pellet. “We are pleased to have reached this significant milestone,” said Brady Granier, […]
Study shows reduced HbA1c with Abbott FreeStyle Libre 2 CGM
Abbott (NYSE:ABT) announced today that a new study supports the use of its FreeStyle Libre 2 continuous glucose monitor (CGM). The study, published in The New England Journal of Medicine, evaluated adults with type 1 diabetes and suboptimal glycemic control. It demonstrated significant reductions in glycated hemoglobin (HbA1c) compared to self-monitoring of blood glucose. Subjects […]
Published data backs digital therapeutic for diabetes from Better Therapeutics
Better Therapeutics (Nasdaq:BTTX) announced today that newly published data supports its digital therapeutic for type 2 diabetes. San Francisco-based Better Therapeutics develops the BT-001 prescription digital therapeutic (PDT). It potentially represents the first-in-class PDT using cognitive behavioral therapy (CBT) to treat type 2 diabetes. In July, the company completed the pivotal trial for its BT-001 digital therapeutic […]
